Todd Franklin Watanabe - Feb 28, 2023 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Signature
/s/ Scott Burrows, as Attorney-in-Fact for Todd Franklin Watanabe
Stock symbol
ARQT
Transactions as of
Feb 28, 2023
Transactions value $
-$124,483
Form type
4
Date filed
3/2/2023, 06:06 PM
Previous filing
Feb 15, 2023
Next filing
Mar 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Sale -$37.9K -2.34K -0.62% $16.17 375K Feb 28, 2023 Direct F1, F2
transaction ARQT Common Stock Sale -$85.5K -5.4K -1.44% $15.82 369K Mar 2, 2023 Direct F1, F3
transaction ARQT Common Stock Sale -$1.14K -69 -0.02% $16.52 369K Mar 2, 2023 Direct F1
holding ARQT Common Stock 17.9K Feb 28, 2023 By Trust F4
holding ARQT Common Stock 17.9K Feb 28, 2023 By Trust F5
holding ARQT Common Stock 125K Feb 28, 2023 By Trust F6
holding ARQT Common Stock 57.4K Feb 28, 2023 By LLC F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
F2 The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F5 The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F6 The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F7 The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Remarks:

Reporting Person's title: Chief Executive Officer and President